Mukul Agrawal is a renowned Indian investor known for his sharp stock-picking skills and value-driven investment approach. With a diversified portfolio across sectors like finance, healthcare, and manufacturing, he has earned a strong reputation in the Indian stock market. His strategic investments and timely entries have consistently delivered impressive returns, making him a respected name among market participants. As per the latest corporate shareholdings filed, Mukul Agrawal publicly holds 71 stocks with a net worth of over Rs. 7,569.2 Cr.
Here are the stocks that gave a multibagger return in Mukul Agrawal’s portfolio in the last 1 year;
Osel Devices Ltd
Osel Devices Ltd is a rapidly expanding medical technology company specializing in advanced diagnostic, radiology, and critical-care equipment. With a strong focus on innovation and affordability, it develops healthcare solutions aimed at improving clinical outcomes and enhancing accessibility across hospitals, clinics, and diagnostic centers. With a market capitalisation of Rs 1,349 crore, the shares closed at Rs 775 per share, decreased around 4 percent as compared to the previous closing price.
Osel Devices has delivered exceptional returns, with a staggering 267% gain over the past year and 160% in just six months, reflecting strong market momentum. Since listing, the stock surged an astounding 305%, underscoring its robust long-term performance and investor confidence in India’s capital markets and economic growth trajectory.
As of September 2025, ace investor Mukul Agrawal holds 1,338,400 shares, representing a 7.6% stake, reflecting strong confidence in the company’s potential. In H1FY26, the company posted impressive financials with revenue at Rs 147 crore and a robust net profit of Rs 15 crore, showcasing strong growth momentum and solid business fundamentals.
Zota Healthcare Ltd
Zota Healthcare Ltd is a pharmaceutical company known for its branded generics, OTC products, and nutraceuticals. Through its Davaindia retail pharmacy chain, the firm focuses on affordable medicines, wide product accessibility, and consistent portfolio expansion within India’s growing healthcare market. With a market capitalisation of Rs 5,111 crore, the shares closed at Rs 1,649 per share, increased around 0.92 percent as compared to the previous closing price.
Zota Healthcare has delivered exceptional returns, with a staggering 201% gain over the past year and 68% in just six months, reflecting strong market momentum. Over a five-year period, returns surged by 1,080%, underscoring its robust long-term performance and investor confidence in India’s capital markets and economic growth trajectory.
As of September 2025, ace investor Mukul Agrawal holds 2,516,989 shares, representing an 8.2 percent stake, reflecting strong confidence in the company’s potential.
ASM Technologies Ltd
ASM Technologies Ltd is a global engineering and product-development services company specialising in digital engineering, cloud, IoT, and semiconductor design. It partners with leading enterprises to deliver innovative solutions across automation, product lifecycle services, and technology modernisation, supporting clients’ global transformation needs. With a market capitalisation of Rs 5,335 crore, the shares closed at Rs 3,658 per share, decreased around 3.01 percent as compared to the previous closing price.
ASM Technologies has delivered exceptional returns, with a staggering 155% gain over the past year and 78.29% in just six months, reflecting strong market momentum. Over five years, returns surged an astounding 5,066.41%, underscoring its robust long-term performance and investor confidence in India’s capital markets and economic growth trajectory.
As of September 2025, ace investor Mukul Agrawal holds 1,500,000 shares, representing a 10.7% stake, reflecting strong confidence in the company’s potential. In Q2FY26, the company posted impressive financials with revenue at Rs 154 crore and a robust net profit of Rs 19 crore, showcasing strong growth momentum and solid business fundamentals.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
